FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1828157025> ?p ?o ?g. }

• W1828157025 endingPage "3535" @default.
• W1828157025 startingPage "3528" @default.
• W1828157025 abstract "Abstract The phlogistic actions of six molecular species of platelet-activating factor (PAF) (1-O-alkyl-PAF homologs, 16:0-, 18:0- and 18:1-alkyl-PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC) and their respective 1-acyl-PAF analog counterparts, 16:0-, 18:0- and 18:1-acyl-PAF, 1-acyl-2-acetyl-sn-glycero-3-phosphocholine (AGPC)) were assessed relative to five human neutrophilic polymorphonuclear leukocyte (PMN) functional responses: 1) lysosomal enzyme secretion; 2) specific desensitization to 16:0-AGEPC-induced lysosomal enzyme secretion; 3) O2- production; 4) chemotaxis; and 5) priming for enhanced O2- production. With respect to inducing lysozyme secretion, 18:0-AGEPC was 30- and 75-fold less potent than 16:0-AGEPC and 18:1-AGEPC, respectively, and was 25- and 40-fold less potent for inducing beta-glucuronidase secretion. 18:0-AGEPC was also 10-fold less active than 18:1- and 16:0-AGEPC for inducing O2- production. Thus, the rank order of potency of the alkyl-PAF homologs for inducing both lysosomal enzyme secretion and O2- production was 18:1- greater than or equal to 16:0- much greater than 18:0-AGEPC. In contrast, these three alkyl-PAF homologs had the same potency for desensitizing PMN to subsequent 16:0-AGEPC-induced lysosomal enzyme secretion and for priming PMN for augmented O2- production in response to FMLP or human recombinant C5a. Paradoxically, however, the rank order of potency of the alkyl-PAF homologs for effecting PMN chemotaxis was 18:0- greater than 18:1- much greater than 16:0-AGEPC. At concentrations as high as 1.0 microM, the acyl-PAF analogs did not initiate PMN lysosomal enzyme secretion, O2- production, or chemotaxis. However, the acyl-PAF analogs induced partial PMN desensitization to 16:0-AGEPC. A novel finding of potential (patho)-physiologic significance was the ability of acyl-PAF at nM concentrations to prime PMN for significantly enhanced O2- production after stimulation with FMLP or human recombinant C5a. The priming action of acyl-PAF was due to an increase in the rate as opposed to a prolongation of O2- production. The differing rank orders of potency of the alkyl-PAF homologs and acyl-PAF analogs for stimulating several physiologic responses of the same target cell, the human PMN, support the premise that there may be more than one PAF receptor subtype on the PMN and/or that differences in the biophysical properties of the various molecular species of PAF modulate their interaction with PAF receptor(s) linked to stimulus-response coupling." @default.
• W1828157025 created "2016-06-24" @default.
• W1828157025 creator A5006699242 @default.
• W1828157025 creator A5012766676 @default.
• W1828157025 creator A5014974894 @default.
• W1828157025 creator A5015280359 @default.
• W1828157025 creator A5028582089 @default.
• W1828157025 creator A5036777163 @default.
• W1828157025 creator A5040263769 @default.
• W1828157025 creator A5083133515 @default.
• W1828157025 date "1992-06-01" @default.
• W1828157025 modified "2023-10-10" @default.
• W1828157025 title "Differential responsiveness of human neutrophils to the autocrine actions of 1-O-alkyl-homologs and 1-acyl analogs of platelet-activating factor." @default.
• W1828157025 doi "https://doi.org/10.4049/jimmunol.148.11.3528" @default.
• W1828157025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1316919" @default.
• W1828157025 hasPublicationYear "1992" @default.
• W1828157025 type Work @default.
• W1828157025 sameAs 1828157025 @default.
• W1828157025 citedByCount "17" @default.
• W1828157025 crossrefType "journal-article" @default.
• W1828157025 hasAuthorship W1828157025A5006699242 @default.
• W1828157025 hasAuthorship W1828157025A5012766676 @default.
• W1828157025 hasAuthorship W1828157025A5014974894 @default.
• W1828157025 hasAuthorship W1828157025A5015280359 @default.
• W1828157025 hasAuthorship W1828157025A5028582089 @default.
• W1828157025 hasAuthorship W1828157025A5036777163 @default.
• W1828157025 hasAuthorship W1828157025A5040263769 @default.
• W1828157025 hasAuthorship W1828157025A5083133515 @default.
• W1828157025 hasConcept C134018914 @default.
• W1828157025 hasConcept C170493617 @default.
• W1828157025 hasConcept C185592680 @default.
• W1828157025 hasConcept C2779020240 @default.
• W1828157025 hasConcept C49039625 @default.
• W1828157025 hasConcept C54166955 @default.
• W1828157025 hasConcept C55493867 @default.
• W1828157025 hasConcept C86803240 @default.
• W1828157025 hasConceptScore W1828157025C134018914 @default.
• W1828157025 hasConceptScore W1828157025C170493617 @default.
• W1828157025 hasConceptScore W1828157025C185592680 @default.
• W1828157025 hasConceptScore W1828157025C2779020240 @default.
• W1828157025 hasConceptScore W1828157025C49039625 @default.
• W1828157025 hasConceptScore W1828157025C54166955 @default.
• W1828157025 hasConceptScore W1828157025C55493867 @default.
• W1828157025 hasConceptScore W1828157025C86803240 @default.
• W1828157025 hasIssue "11" @default.
• W1828157025 hasLocation W18281570251 @default.
• W1828157025 hasLocation W18281570252 @default.
• W1828157025 hasOpenAccess W1828157025 @default.
• W1828157025 hasPrimaryLocation W18281570251 @default.
• W1828157025 hasRelatedWork W1966999334 @default.
• W1828157025 hasRelatedWork W1981687944 @default.
• W1828157025 hasRelatedWork W1995418745 @default.
• W1828157025 hasRelatedWork W2022075480 @default.
• W1828157025 hasRelatedWork W2030286723 @default.
• W1828157025 hasRelatedWork W2033790133 @default.
• W1828157025 hasRelatedWork W2401207354 @default.
• W1828157025 hasRelatedWork W2734207448 @default.
• W1828157025 hasRelatedWork W3162469281 @default.
• W1828157025 hasRelatedWork W4253617259 @default.
• W1828157025 hasVolume "148" @default.
• W1828157025 isParatext "false" @default.
• W1828157025 isRetracted "false" @default.
• W1828157025 magId "1828157025" @default.
• W1828157025 workType "article" @default.